Medicamen Biotec

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE646B01010
  • NSEID: MEDICAMEQ
  • BSEID: 531146
INR
286.75
1.7 (0.6%)
BSENSE

Nov 20

BSE+NSE Vol: 5.37 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Cr
Consolidate Quarterly Results
Sep'26
Jun'26
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Net Sales
54.83
47.90
60.65
46.91
47.17
43.04
29.61
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
54.83
47.90
60.65
46.91
47.17
43.04
29.61
Raw Material Cost
11.07
22.61
26.09
21.69
21.97
24.60
11.52
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
10.91
-1.49
6.10
2.02
1.18
-1.88
2.25
Employee Cost
9.65
9.31
9.40
8.37
8.83
8.09
8.40
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.01
0.00
0.00
-0.01
-0.01
Selling and Distribution Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Expenses
14.52
13.14
13.61
10.45
10.03
7.63
9.06
Total Expenditure (Excl Depreciation)
46.15
43.57
55.21
42.53
42.01
38.43
31.22
Operating Profit (PBDIT) excl Other Income
8.68
4.33
5.44
4.38
5.16
4.61
-1.61
Other Income
0.00
0.86
1.74
0.53
0.37
0.47
5.23
Operating Profit (PBDIT)
8.68
5.19
7.18
4.91
5.53
5.08
3.62
Interest
1.69
0.83
0.38
0.97
0.99
1.15
0.65
Exceptional Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Gross Profit (PBDT)
6.99
4.36
6.80
3.94
4.54
3.93
2.97
Depreciation
1.87
1.79
1.73
1.83
1.86
1.80
0.48
Profit Before Tax
5.12
2.57
5.06
2.11
2.68
2.13
2.49
Tax
1.00
0.73
0.61
0.48
0.57
0.53
0.63
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
4.12
1.85
4.45
1.63
2.11
1.60
1.86
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
4.12
1.85
4.45
1.63
2.11
1.60
1.86
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.71
-0.27
0.59
-0.55
-0.55
-0.55
-0.55
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
3.41
2.12
3.86
2.19
2.67
2.15
2.42
Equity Capital
13.56
13.56
13.56
13.56
13.56
13.56
12.71
Face Value
10.0
10.0
10.0
10.0
10.0
10.0
10.0
Reserves
267.95
0.00
0.00
0.00
0.00
0.00
0.00
Earnings per share (EPS)
2.51
1.56
2.85
1.62
1.97
1.59
1.9
Diluted Earnings per share
3.04
1.36
3.28
1.21
1.56
1.18
1.47
Operating Profit Margin (Excl OI)
15.83%
9.04%
8.97%
9.34%
10.94%
10.71%
-5.44%
Gross Profit Margin
12.75%
9.1%
11.21%
8.4%
9.62%
9.13%
10.03%
PAT Margin
7.51%
3.86%
7.34%
3.47%
4.47%
3.72%
6.28%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Sep 2026 is 16.24% vs 5.43% in Sep 2025

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Sep 2026 is 27.72% vs 82.88% in Sep 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Sep 2026 is 68.22% vs -2.82% in Sep 2025

stock-summary

Interest

YoY Growth in quarter ended Sep 2026 is 70.71% vs -4.81% in Sep 2025

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Sep 2026 has improved from Sep 2025

Compare Quarterly Results Of Medicamen Biotec With
Markets Mojo
Figures in Cr
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
54.83
0
54.83
Other Operating Income
0.00
0.00
0.00
Total Operating income
54.83
0
54.83
Raw Material Cost
11.07
0
11.07
Purchase of Finished goods
0.00
0
0.00
(Increase) / Decrease In Stocks
10.91
0
10.91
Employee Cost
9.65
0
9.65
Power Cost
0.00
0
0.00
Manufacturing Expenses
0.00
0
0.00
Selling and Distribution Expenses
0.00
0
0.00
Other Expenses
14.52
0.00
14.52
Total Expenditure (Excl Depreciation)
46.15
0
46.15
Operating Profit (PBDIT) excl Other Income
8.68
0.00
8.68
Other Income
0.00
0
0.00
Operating Profit (PBDIT)
8.68
0
8.68
Interest
1.69
0
1.69
Exceptional Items
0.00
0
0.00
Gross Profit (PBDT)
6.99
0
6.99
Depreciation
1.87
0
1.87
Profit Before Tax
5.12
0
5.12
Tax
1.00
0
1.00
Provisions and contingencies
0.00
0
0.00
Profit After Tax
4.12
0
4.12
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0.00
0
0.00
Other Adjustments
0.00
0
0.00
Net Profit
4.12
0
4.12
Share in Profit of Associates
0.00
0
0.00
Minority Interest
0.71
0
0.71
Other related items
0.00
0.00
0.00
Consolidated Net Profit
3.41
0
3.41
Equity Capital
13.56
0
13.56
Face Value
10.00
0
0.00
Reserves
267.95
0
267.95
Earnings per share (EPS)
2.51
0
2.51
Diluted Earnings per share
3.04
0
3.04
Operating Profit Margin (Excl OI)
15.83%
0%
0.00
15.83%
Gross Profit Margin
12.75%
0%
0.00
12.75%
PAT Margin
7.51%
0%
0.00
7.51%
Public Share Holdings (%)
0.00%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 54.83 Cr
in Sep 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Sep 2026 is 14.47% vs -21.02% in Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 is 16.24% vs 5.43% in Sep 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 3.41 Cr
in Sep 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Sep 2026 is 60.85% vs -45.08% in Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 is 27.72% vs 82.88% in Sep 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 8.68 Cr
in Sep 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Sep 2026 is 100.46% vs -20.40% in Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 is 68.22% vs -2.82% in Sep 2025

Quarterly - Interest
Interest 1.69 Cr
in Sep 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Sep 2026 is 103.61% vs 118.42% in Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 is 70.71% vs -4.81% in Sep 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 15.83%
in Sep 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Sep 2026 has improved from Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 has improved from Sep 2025